[ad_1]
Under the European Union agreement with Pfizer / BioNTech, it was announced that it will pay 4.65 billion euros (about 42 billion Turkish lira) for 300 million doses.
Turkish scientist Prof. Dr. Uğur Şahin and Prof. Dr. There has been a new development regarding the vaccine candidate BNT162b1, which was jointly developed by BioNTech, owned by Özlem Türeci, and Pfizer from the United States.
As part of the EU agreement with the company that makes the coronavirus vaccine, it was announced that it will pay 4.65 billion euros (about 42 billion Turkish lira) for 300 million doses. The cost of the vaccine administered in two doses corresponds to approximately 31 euros (280 TL) in European countries.
It has been announced that it will be 95% effective
The Pfizer / BioNTech vaccine was announced to provide greater than 95% protection in Phase 3 clinical trial results. In the statement released by Pfizer, it is stated that an application will be submitted to the US Food and Drug Administration (FDA) next Friday for approval for emergency use.
.
[ad_2]
Source link
